What Is Orforglipron (Foundayo)? The Oral GLP-1 Tablet Explained

The GLP-1 field has been dominated by injectable medicines, but one of the most significant developments in metabolic research is the arrival of orforglipron, now known by the brand name Foundayo.

Unlike peptide-based GLP-1 medicines, orforglipron is a small-molecule GLP-1 receptor agonist designed to be taken orally.

That distinction is important. It represents an attempt to achieve GLP-1 receptor activation without relying on an injectable peptide — and could signal a much broader shift in the way metabolic medicines are developed.

In August 2026, the UK became the first country in Europe to authorise orforglipron, following a large Phase 3 clinical development programme. 

So what exactly is orforglipron, how does it differ from existing GLP-1 medicines, and why has it attracted so much attention?

What is orforglipron?

Orforglipron is an oral, non-peptide GLP-1 receptor agonist developed by Eli Lilly.

GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone involved in several aspects of metabolic regulation.

Medicines such as semaglutide and tirzepatide have demonstrated how powerful targeting incretin pathways can be.

Orforglipron approaches the GLP-1 receptor differently.

Rather than being a peptide molecule, it is a small chemical molecule capable of activating the GLP-1 receptor. Lilly describes LY3502970 (orforglipron) as a chemical entity acting as a GLP-1 receptor agonist. 

This allows it to be formulated as a conventional tablet.

Is orforglipron a peptide?

No.

This is one of the most important differences between orforglipron and many established GLP-1 medicines.

Semaglutide, for example, is a peptide-based GLP-1 receptor agonist.

Orforglipron is a non-peptide small molecule.

Researchers have spent years trying to develop small molecules capable of effectively activating receptors traditionally targeted by peptide drugs.

Orforglipron demonstrates that GLP-1 receptor activation does not necessarily require a peptide structure.

For peptide and metabolic researchers, this makes the compound particularly interesting because it represents an alternative technological approach to targeting the same biological pathway.

Is orforglipron a tablet?

Yes.

Orforglipron is taken once daily as an oral tablet.

Perhaps more importantly, it can be taken without food or water restrictions. 

This differentiates it from oral semaglutide formulations that have historically required specific administration conditions to achieve adequate absorption.

The development of an effective small-molecule GLP-1 receptor agonist potentially removes some of the absorption difficulties associated with delivering peptide medicines orally.

What is Foundayo?

Foundayo is the brand name for orforglipron.

In the UK, the MHRA authorised Foundayo in August 2026 for weight management in eligible adults and for improving glycaemic control in adults with insufficiently controlled type 2 diabetes. 

This is worth clarifying because searches for “orforglipron” and “Foundayo” now refer to the same active medicine.

Older research papers and clinical trials will generally use the name orforglipron.

How does orforglipron work?

Orforglipron activates the GLP-1 receptor.

GLP-1 signalling has several physiological roles associated with metabolic regulation, including effects on insulin secretion, glucagon signalling, gastrointestinal function and appetite regulation.

What makes orforglipron scientifically unusual isn’t necessarily the receptor it targets — researchers already understand GLP-1 signalling relatively well.

It is how the receptor is being targeted.

A comparatively small non-peptide molecule is producing pharmacological activation of a receptor that has become strongly associated with peptide therapeutics.

That could have implications extending considerably beyond one medicine.

Orforglipron vs oral semaglutide: what’s the difference?

Both target the GLP-1 receptor, but they are structurally very different.

Semaglutide is peptide-based. Orforglipron is a small molecule.

That difference affects how the compounds can be formulated and absorbed.

A Phase 3 head-to-head study, ACHIEVE-3, directly compared orforglipron with oral semaglutide in adults with type 2 diabetes.

In the study, the investigated orforglipron regimen produced greater reductions in both HbA1c and body weight than the oral semaglutide comparator. The findings were subsequently published in The Lancet. 

That doesn’t mean every GLP-1 medicine can be ranked simply by one study. Different populations, formulations, doses and clinical objectives matter.

But the results demonstrated that a non-peptide oral GLP-1 agonist can produce substantial biological effects.

What did the orforglipron trials find?

Orforglipron has now progressed through an extensive Phase 3 programme.

Studies have examined it in obesity and type 2 diabetes, including the ATTAIN and ACHIEVE programmes.

The clinical programme has reported reductions in body weight and HbA1c across different populations. More recent cardiovascular data from ACHIEVE-4 also met the study’s primary cardiovascular safety objective. 

This evidence base ultimately supported regulatory submissions and approvals.

That’s an important distinction from many emerging metabolic compounds we discuss at Klarity Research: orforglipron has moved beyond early-stage experimental research into an authorised medicine.

Is orforglipron available in the UK?

Yes — but this is a very recent development.

The MHRA authorised orforglipron (Foundayo) on 10 August 2026, making the UK the first European country to authorise the medicine. 

Its authorised uses include weight management for eligible adults and treatment of insufficiently controlled type 2 diabetes.

Authorisation should not be confused with unrestricted availability or suitability for everybody. Prescription access and individual eligibility are separate issues.

Why is orforglipron important for metabolic research?

The significance of orforglipron goes beyond one GLP-1 medicine.

For years, one of the major limitations of therapeutic peptides has been oral bioavailability.

Peptides can be broken down within the digestive system and often struggle to cross biological membranes efficiently.

Researchers have therefore explored numerous approaches to oral peptide delivery.

Orforglipron presents another possibility:

Don’t deliver the peptide orally at all. Develop a small molecule capable of activating the same receptor.

That could become an increasingly important strategy in drug development.

Are oral medicines replacing injectable GLP-1s?

Probably not in any simple sense.

Injectable peptide medicines have characteristics that may remain advantageous in particular applications, while oral small molecules offer a different set of properties.

Instead, metabolic research appears to be moving towards greater diversity.

Researchers are now investigating:

• peptide and non-peptide GLP-1 agonists;
• dual and triple receptor agonists;
• amylin analogues;
• glucagon-containing combinations;
• GIP agonism and antagonism;
• melanocortin signalling;
• activin pathways;
• mitochondrial-derived peptides;
• and entirely new metabolic targets.

This is exactly the shift we’ve been documenting throughout the recent Klarity Research series.

What could come after orforglipron?

Perhaps the most interesting question isn’t whether tablets will replace injections.

It’s what the success of compounds such as orforglipron could encourage researchers to attempt next.

If receptors traditionally associated with peptide hormones can increasingly be targeted using orally available small molecules, researchers may gain a much larger toolkit for influencing metabolic signalling.

That opens questions around pharmacokinetics, receptor selectivity, combination therapies and entirely new classes of oral metabolic compounds.

The bigger picture

Orforglipron illustrates how rapidly metabolic science is changing.

The field has progressed from individual GLP-1 agonists towards dual agonists, triple agonists, amylin-based approaches, novel signalling pathways and now increasingly sophisticated oral small-molecule therapies.

For researchers following peptide science, that’s particularly interesting.

The future may not belong exclusively to peptides or small molecules.

It may involve researchers selecting whichever molecular platform provides the most effective way of influencing a particular biological pathway.

At Klarity Research, we’ll continue following emerging peptide and metabolic research as the science develops.

For educational and research information only. This article is not medical advice.